CagriSema (Cagrilintide + Semaglutide): Fixed-Dose Combo Research, Mechanism, and 2026 Trial Data

Product Deep Dive | 2026-07-09 | 10 min read

A 2026 research guide to CagriSema (cagrilintide + semaglutide): dual-component mechanism, fixed-dose combination rationale, Phase 3 REDEFINE-1 results, amino acid sequences, and COA considerations for combination research.

What is CagriSema

CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist) in a single subcutaneous injection. The combination targets two complementary appetite pathways simultaneously: the GLP-1 receptor and the amylin receptor.

Phase 3 REDEFINE-1 trial (2024) showed 22.7% body weight reduction at 68 weeks for CagriSema, making it competitive with tirzepatide and retatrutide despite being a two-component rather than multi-agonist approach.

Dual-component mechanism

Two distinct mechanisms in one injection:

Semaglutide (GLP-1 agonist)

• Activates GLP-1R
• Drives satiety, slows gastric emptying, enhances insulin secretion, suppresses glucagon
• The established weight loss component

Cagrilintide (amylin analog)

• Activates amylin receptors (AMY1, AMY2, AMY3)
• Drives satiety, slows gastric emptying, reduces postprandial glucagon
• The additive appetite suppression component

The amylin and GLP-1 pathways are mechanistically distinct — they do not compete for the same receptor and produce additive rather than redundant effects. The REDESIGN-1 trial confirmed this: combination produced more weight loss than either component at the same dose.

Amino acid sequences

Semaglutide: Modified human GLP-1(7-37) analog with:

• Aib at position 8
• Lys at position 26 with C18 fatty diacid conjugation
• Lys at position 34
• C-terminal amide

Cagrilintide: Modified human amylin analog with:

• Pro at position 2 (reduces fibril formation vs. native amylin)
• Arg at position 18 and position 34 (improves solubility)
• C-terminal amide
• 25-amino acid sequence (vs. 37 for semaglutide)

Both components are available separately as research peptides for mechanistic studies.

Fixed-dose combination rationale

Fixed-dose combinations offer three advantages over co-administered separate injections:

• **Compliance** — one injection vs. two improves adherence
• **Pharmacokinetic matching** — co-formulation aligns the half-lives of both components
• **Dosing simplicity** — one pen instead of two reduces user error

The REDEFINE-1 Phase 3 trial used a single pre-filled pen with cagrilintide (2.4mg or 4.5mg) and semaglutide (2.4mg).

Phase 3 REDEFINE-1 results (2024)

Key outcomes at 68 weeks:

• CagriSema 4.5mg/2.4mg: 22.7% body weight reduction
• Semaglutide 2.4mg alone: ~13% body weight reduction (historical)
• Cagrilintide 4.5mg alone: ~18% body weight reduction (REDESIGN-1)
• ≥20% weight loss achieved by 57% of CagriSema participants

Adverse events: predominantly gastrointestinal (nausea, vomiting), similar profile to semaglutide monotherapy.

Research applications

Laboratory research with the individual components:

• **Semaglutide**: appetite circuit studies, glycemic control mechanisms, cardiometabolic outcomes
• **Cagrilintide**: amylin receptor pharmacology, fibril inhibition studies, combination synergy research

Fixed-dose combination research in preclinical models typically involves co-administration of both components rather than a pre-formulated combination peptide.

COA specification for research peptides

| Test | Method | Acceptance Criterion | | --- | --- | --- | | Appearance | Visual | White to off-white lyophilized powder | | HPLC Purity | RP-HPLC | ≥95% | | MS (ESI) | Mass spectrometry | ±0.5% of theoretical m/z | | Endotoxin | LAL kinetic chromogenic | <1.0 EU/mg | | Water content | KF titration | <3% |

Sourcing

CagriSema is not commercially available as a finished product for research. The individual components — cagrilintide and semaglutide — are available as research peptides for laboratory use.

ZePeptide supplies both cagrilintide and semaglutide with ≥95% HPLC purity, full COA documentation, and validated cold-chain packaging.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.